Identity recordFDA-approved US medicine with country-specific status elsewhere
What Orforglipron / Foundayo resolves to
FOUNDAYO is an FDA-approved US oral medicine containing the non-peptide small molecule orforglipron. That US approval does not establish authorization, launch, prescription access, market presence, supply, or seller authority in another country, and it does not authenticate a same-name research or imported product.
- Evidence lane
- FDA-approved medicine
- Current record
- NDA 220934 · FDA-approved prescription drug
- Checked
- July 20, 2026
orforglipronFoundayoLY3502970NDA 220934oral GLP-1
Destination recordActive QUEST3+ record required
What Malaysia still has to prove
A Malaysia guide to checking peptide-related products in NPRA's QUEST3+ search, matching the MAL registration number, and separating product and supplier licensing claims.
- Comparison mode
- MYR / NPRA product and licensing records
- Price coverage
- No qualified Malaysia seller table
- Guide updated
- July 18, 2026